Payment overview · 2025
General Payments
$917.17
38 reported records · 13 companies
Healthcare provider profile · identity verified
Inna Abramova, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1467487801
Verified facts
What the public records show
CMS Open Payments records show Inna Abramova, MD received $917.17 in general payments during 2025 across 38 reported records.
ABBVIE INC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Linzess, Mounjaro, Ozempic, Prolia, Qulipta, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 373 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 373 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.91 | 20.2% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $118.09 | 12.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.82 | 12.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.28 | 10.4% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $92.35 | 10.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.34 | 8.5% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $74.84 | 8.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.73 | 4.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.97 | 3.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.44 | 3.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.92 | 2.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.48 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.00 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $917.17 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $133.29 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $97.17 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $95.28 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $92.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.34 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $74.84 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.30 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.30 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $66.52 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $55.19 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $46.79 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 133 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 373 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 246 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 205 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
133 | 33 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
246 | 52 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
143 | 28 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
139 | 32 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
373 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
205 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
373 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1052 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 1021 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 134 |
| Omeprazole | Omeprazole | 621 | 116 |
| Metformin Hcl | Metformin Hcl | 615 | 124 |
| Losartan Potassium | Losartan Potassium | 583 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 464 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 70 |
| Gabapentin | Gabapentin | 418 | 99 |
| Furosemide | Furosemide | 376 | 68 |
| Eliquis | Apixaban | 373 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 326 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 325 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 319 | 51 |
| Jardiance | Empagliflozin | 272 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 263 | 43 |
| Sertraline Hcl | Sertraline Hcl | 258 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 50 |
| Linzess | Linaclotide | 246 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 91 |
| Vascepa | Icosapent Ethyl | 217 | 40 |
| Trazodone Hcl | Trazodone Hcl | 213 | 31 |
| Glimepiride | Glimepiride | 208 | 44 |
| Ozempic | Semaglutide | 205 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 46 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 192 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 30 |
| Carvedilol | Carvedilol | 187 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 182 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 41 |
| Valsartan | Valsartan | 181 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 181 | 36 |
| Allopurinol | Allopurinol | 172 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 38 |
| Donepezil Hcl | Donepezil Hcl | 166 | 30 |
| Potassium Chloride | Potassium Chloride | 160 | 29 |
| Ezetimibe | Ezetimibe | 159 | 32 |
| Atenolol | Atenolol | 148 | 28 |
| Simvastatin | Simvastatin | 148 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 147 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 145 | 27 |
| Clonidine Hcl | Clonidine Hcl | 143 | 47 |
| Synthroid | Levothyroxine Sodium | 143 | 28 |
| Zenpep | Lipase/Protease/Amylase | 139 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 37 |
| Meloxicam | Meloxicam | 136 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 25 |
| Januvia | Sitagliptin Phosphate | 135 | 22 |
| Creon | Lipase/Protease/Amylase | 133 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 131 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 15 |
| Azithromycin | Azithromycin | 126 | 103 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 123 | 27 |
| Prednisone | Prednisone | 123 | 65 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 122 | 23 |
| Lisinopril | Lisinopril | 121 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 18 |
| Finasteride | Finasteride | 118 | 23 |
| Enalapril Maleate | Enalapril Maleate | 112 | 15 |
| Ibuprofen | Ibuprofen | 111 | 50 |
| Meclizine Hcl | Meclizine Hcl | 105 | 32 |
| Famotidine | Famotidine | 102 | 34 |
| Ammonium Lactate | Ammonium Lactate | 101 | 51 |
| Glipizide Er | Glipizide | 99 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 17 |
| Entresto | Sacubitril/Valsartan | 97 | 19 |
| Lidocaine | Lidocaine | 95 | 19 |
| Spironolactone | Spironolactone | 94 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 91 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 90 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 90 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 86 | 13 |
| Nifedipine Er | Nifedipine | 83 | 18 |
| Ranolazine Er | Ranolazine | 83 | 14 |
| Mirtazapine | Mirtazapine | 82 | 17 |
| Repatha Sureclick | Evolocumab | 75 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 74 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 61 |
| Ventolin Hfa | Albuterol Sulfate | 70 | 13 |
| Tramadol Hcl | Tramadol Hcl | 68 | 16 |
| Hydrocortisone | Hydrocortisone | 66 | 26 |
| Montelukast Sodium | Montelukast Sodium | 60 | 12 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 60 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 28 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Trulicity | Dulaglutide | 55 | suppressed |
| Febuxostat | Febuxostat | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Clotrimazole | Clotrimazole | 53 | 28 |
| Glipizide | Glipizide | 53 | 12 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 49 | suppressed |
| Dutasteride | Dutasteride | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Ursodiol | Ursodiol | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 11 |
| Celecoxib | Celecoxib | 45 | 14 |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 45 | 38 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Mupirocin | Mupirocin | 42 | 33 |
| Nitroglycerin Patch | Nitroglycerin | 42 | suppressed |
| Telmisartan | Telmisartan | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 40 | 15 |
| Torsemide | Torsemide | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Methimazole | Methimazole | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 28 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Naproxen | Naproxen | 27 | 13 |
| Clonidine | Clonidine | 26 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 14 |
| Baclofen | Baclofen | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Crestor | Rosuvastatin Calcium | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diovan | Valsartan | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Rapaflo | Silodosin | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Uloric | Febuxostat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $917.17 · 38 records | ABBVIE INC. | ABRYSVO, ACCRUFER, Auvelity, CAMZYOS, CAPVAXIVE, COMIRNATY, CREON, ELIQUIS, EVENITY, IBSRELA, KISUNLA, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VENASEAL, VERQUVO, VRAYLAR, ZAVZPRET, ZENPEP, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error